NATALEE

1. 00:15
   x.com

   Honored to be part of this discussion with OncoDaily and esteemed colleagues on the 6-year NATALEE data and its implications for breast cancer care.

1. 23:49
   x.com

   Oncologists Discuss NATALEE Trial
2. 23:36
   x.com

   #ESMO26 | Per la rubrica #OncoSTEPS Armando Orlandi commenta l’update a 6 anni dello studio NATALEE.👇
3. 23:15
   x.com

   Six-year NATALEE data at #ESMO2026: adjuvant ribociclib plus an NSAI reduced the risk of death by 19% vs endocrine therapy alone in HR+/HER2− early breast cancer. Company-reported;
4. 23:00
   x.com

   🚨 NATALEE: Kisqali® + ET reduced death risk by ~20% in high-risk HR+/HER2− early breast cancer (OS HR 0.809). 6-year iDFS benefit: 5.3%.
5. 22:55
   x.com

   🤩 @OncBrothers highlighting 🔑 studies presented on Day 1 of #ESMO26
6. 22:16
   mp.weixin.qq.com
7. 21:15
   x.com

   📍 Live from #ESMO26 in Madrid!
8. 20:36
   x.com

   #NATALEE at 6 years: sustained iDFS benefit with adjuvant ribociclib.
9. 19:06
   x.com

   ESMO 2026’nın ilk gününden seçtiklerimiz Onkoloji Gazetesi’nde.
10. 18:18
    x.com

    עדכונים נוספים מהכנס:
11. 15:46
    x.com

    24-hour top trending trials we're tracking at #ESMO26 as we start day 2, based on posts by validated HCPs on social media:
12. 10:40
    mp.weixin.qq.comPick

    NATALEE Six-Year Follow-up Shows Kisqali Plus Endocrine Therapy Cuts Death Risk 19% in High-Risk HR+/HER2- Early Breast Cancer

    Novartis announced six-year follow-up results from the phase 3 NATALEE trial. In patients with high recurrence risk HR+/HER2- early breast cancer, Kisqali (ribociclib) plus endocrine therapy reduced the risk of death by 19% compared with endocrine therapy alone (HR=0.809, 95% CI 0.661-0.989).

13. 04:42
    x.com

    #ScienceLink #Madrid2026 #ESMO26 #NATALEE #Ribociclib
14. 04:09
    x.com

    NATALEE: Adjuvant Ribociclib Plus NSAI Improves Long-Term Survival in HR+/HER2- Early Breast Cancer
15. 01:42
    x.com

    Encouraging 6-year #NATALEE results presented at #ESMO26 ! 🎯
16. 01:22
    x.com

    Day 1 #ESMO26 highlights
17. 00:31
    x.com

    Clear, compact NATALEE OS summary from @stolaney1. The detail fellows mix up: NATALEE used ribociclib 400 mg for 3 years and included high-risk node-negative stage II disease, whil
18. 00:25
    x.com

    🚨 #ESMO26 moves fast your inbox should help you keep up, not add more noise.

1. 23:42
   x.com

   🚨 Day 1 highlights from #ESMO26 are here!
2. 23:21
   x.com

   🚨 The daily OncoAlert Newsletter is LIVE from Madrid 🇪🇸 #ESMO26
3. 22:47
   x.com

   #ESMO26 | NATALEE: 6-year outcomes
4. 21:32
   x.com

   NATALEE 6-y results are out! #ESMO26
5. 21:07
   x.com

   At 15y analyses, extended ET did not show an OS benefit. Now both adjuvant abema and ribo have positive OS results. Do you think there is still a role for extending ET after adjuva
6. 21:00
   x.com

   Great news! NATALEE is positive for overall survival. Great presentation from Dr Slamon. Big thanks to all the patients, and research nurses who risked themselves during COVID to
7. 20:56
   x.com

   NATALEE: 6-Year Update at #ESMO26
8. 20:55
   x.com

   Cowabunga! 🌊 Riding the Early & Adjuvant Breast Cancer Wave 🏄🏻‍♂️🤙🏻 from #ESMO26
9. 20:52
   x.com

   @myesmo #ESMO26. The start to an exciting meeting - first two oral BC sessions today. The first session with OS data from Natalee, long term benefit from extended letrozole in B42,
10. 20:51
    x.com

    #ESMO26
11. 20:51
    x.com

    Oral abstract #BreastCancer session at #ESMO26: updated data from NATALEE trial simultaneously published in @Annals_Oncology
12. 20:50
    x.com

    NATALEE 6-year OS analysis shows modest (early…given what we just saw in NSABP42…) improvement in OS.
13. 20:50
    x.com

    📢 #ESMO26 concomitant paper - Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year fol
14. 20:49
    x.com

    NATALEE 6-year analysis demonstrated an OS benefit with adjuvant ribociclib in HR+/HER2− early breast cancer (HR 0.81; absolute benefit 2.1%), with sustained iDFS benefit (HR 0.74;
15. 20:49
    x.com
16. 20:49
    x.com

    6-year results of Natalee (ribociclib): improvements in OS, BCSS, iDFS, DRFS - some subgroups analyses still required
17. 20:48
    x.com

    #ESMO26
18. 20:48
    x.com

    One of the most awaited abstracts of #ESMO26: OS results of the NataLEE trial
19. 20:48
    x.com

    During the NATALEE readout, it's the top trending trial in the live HCP conversation at #ESMO26.
20. 20:47
    x.com

    NATALEE: OS data
21. 20:46
    x.com

    "Not ready to call NATALEE an OS win." @nlindenberg
22. 19:55
    x.com

    Ad #ESMO26 novità per il trattamento di alcune forme di #tumorealseno dai risultati dell'analisi di follow-up a 6 anni dello studio NATALEE.
23. 19:54
    x.com

    Studio di Fase III #NATALEE, presentati ad #ESMO26 i risultati dell’analisi di follow-up a 6 anni.
24. 16:41
    x.com

    Today at #ESMO26, the 6-year results of NATALEE will be presented. Ahead of the presentation, my personal view on the survival gains with adjuvant CDK4/6 inhibitors…
25. 15:28
    x.com

    NATALEE: We’re talking about saving lives!
26. 15:07
    x.com

    #ESMO26
27. 15:01
    x.com

    NATALEE OS: no formal significance; the analysis is descriptive (nominal P, no alpha). monarchE, by contrast, had a prespecified alpha-controlled OS analysis and met it. NATALEE: H
28. 12:37
    x.com

    #ESMO26 | NATALEE – 6-year results (Pre-presentation abstract)
29. 05:20
    x.com

    Right now there's growing anticipation among HCPs for @NovartisCancer NATALEE trial 6-year breast cancer survival results due to be presented at #ESMO26, according to @CREATION Int…
30. 04:45
    x.com

    #ESMO26 tomorrow the 6-y survival results of the NATALEE trial will be presented in Madrid, 2:25 pm

1. 14:12
   x.com

   Six years into NATALEE, the key question is no longer whether adjuvant ribociclib improves iDFS.

1. 03:20
   x.com

   #ESMO26 breast cancer: my ten to watch OS from NATALEE, postMONARCH and FINER. CDK4 with FOURLIGHT-1. Pembro in HR+ with KEYNOTE-B49. T-DXd moves neoadjuvant in TALENT. ADC after …

Heat now 172·Peak in the comparable set 237 (Oct 25 01:00)·Change over 24h in the comparable set -13%·Participants now 42

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.